Development of a neuroimaging biomarker of the pro-coagulant state in Alzheimer's disease: The BioClotAD project Articles uri icon

publication date

  • June 2022


  • 1, suppl


  • 42

International Standard Serial Number (ISSN)

  • 0271-678X

Electronic International Standard Serial Number (EISSN)

  • 1559-7016


  • Alzheimer’s disease (AD) is the most common form of dementia (Alzheimer’s Association, 2021). Its multifactorial profile includes an early haemostatic dysregulation, inducing a pro-thrombotic milieu. Consequently, AD-patients’ brains show increased fibrin levels and degradation-resistant clots, which intensify hypoperfusion, neurodegeneration and blood-brain barrier (BBB) disruption (Cortes-Canteli et al, 2012). These processes appear early in AD’s course, but not in all patients. Early detection of these phenomena would be invaluable to identify patients likely to benefit from anticoagulant therapies (Cortes-Canteli et al, 2019).


  • Biology and Biomedicine